Russia initiated aggression against Ukraine in 2014. On February 24, 2022, it started a full-scale military invasion to the Ukrainian territory. This brutal war and military crimes of Russian troops caused a humanitarian crisis in Ukraine with thousands civilians killed and millions becoming refuges. As a reaction to this act of aggression, many international companies decided to leave the Russian market, while some others continue doing business there as usual. We track such decisions of companies and urge them to stop funding the war.
Hold off investments: company postponing future planned investment/development/marketing while continuing substantive businessPausing Investments
Reducing Activities: company scaling back some business operations while continuing othersScaling Back
Pause operations: company temporarily curtailing operations while keeping return options openSuspension
Clean Break: the company completely halting Russian engagements or exiting RussiaWithdrawal
Exit Completed: company sold its business/assets or its part of the business to a local partner and leaved the marketExit Completed
Stopping all non-essential business in Russia and Belarus, while ensuring continued access to health and agriculture products. In this regard, the company decided to continue supplying agricultural products to Russian farmers. Bayer added that it expects Russian authorities to help protect the free flow of agricultural products, expressing the hope that they will not use the food to put pressure on other countries.
The company suspended all advertising, enrollment in clinical trials, and any additional investment in Russia. It was decided to suspend supply of the personal care products in Russia. The company will continue to supply the medicines and medical devices in the region.
The company stopped any new spending not related to the supply of the essential and life-changing medicines and vaccines in Russia, as well as in Belarus.
The company is not planning any new investments in Russia. It is continuing to work in Russia, and are taking all required measures to ensure an uninterrupted supply of medicines.
The company suspends non-essential business activity in the country, including all new investments, business development and advertising.
Pfizer will donate all profits of the Russian subsidiary to causes that provide direct humanitarian support to the people of Ukraine. There will be no new clinical trials in Russia.
Will continue to supply essential medicines, vaccines, medical devices, and equipment in Russia. Halted clinical trials, advertising, and promotion. Russian sales proceeds to go to humanitarian aid. (No manufacturing and little raw materia/suply chain reliance. Combined Russia and Ukraine sales over $650 K annually)
AbbVie has temporarily suspended operations for the aesthetics products in Russia and paused the start of new clinical studies. Other operations are continued.
March 28: Suspended all new investments in Russia. Shipments to Russia only include essential drugs. Prior to March 28, sold pediatric products and products used for treatment of acute or chornic medical conditions. Donating medications to Ukraine. Does not import any medicines, active ingredients, or raw materials for production from Russia or Belarus. (Akrikhin, a Russian pharmaceutical company, is listed as an asset. Poland's largest drug maker)
Merck to continue supplying essential medicines and vaccines in Russia and will donate any profit from Russia to humanitarian causes, the company will not make further investments in Russia, This includes stopping all promotional activities, capital investments and business development initiatives, Additionally, screening and enrollment in ongoing clinical trials, and planning for new studies in Russia have been suspended,